000			nab a22 7a 4500
999			_c16688 _d16688
003			PC16688
005			20211213134059.0
008			211213b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_91916 _aCaro Teller, José Manuel _eFarmacia
100			_9387 _aCortijo Cascajares, Susana _eFarmacia
100			_91917 _aEscribano Valenciano, Irene _eFarmacia
100			_91918 _aSerrano Garrote, Olga _eFarmacia
100			_9872 _aFerrari Piquero, José Miguel _eFarmacia
245	0	0	_aUso, efectividad y seguridad de abiraterona en cáncer de próstata. _h[artículo]
260			_bFarmacia hospitalaria: órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria, _c2014
300			_a38(2):118-22.
500			_aFormato Vancouver: Caro Teller JM, Cortijo Cascajares S, Escribano Valenciano I, Serrano Garrote O, Ferrari Piquero JM. Uso, efectividad y seguridad de abiraterona en cáncer de próstata. Farm Hosp. 2014 Apr 1;38(2):118-22.
501			_aPMID: 24669896
504			_aContiene 15 referencias
520			_aBackground and objective: After the marketing of Abiraterone, an androgen synthesis inhibitor, the aim of the study was to analyze its use, response, and safety in the population of a tertiary care level hospital. Materials and methods: A retrospective observational study was carried out including all patients that were started on Abiraterone within a 21-month period. Demographical, diagnostic, therapeutic, and clinical variables were gathered. The response was assessed through the decreased of PSA as compared to baseline values. To assess the safety, all treatment-related adverse events were recorded. Results: A total of 45 patients were included of which 88.89% could be assessed for the drug effectiveness. The median baseline PSA value was 457.31 (range 9032-2.81). PSA decrease was ≥ 50%, ≥ 90% and < 30% in 16 (40%), 3 (7.5%) y 20 (50%), respectively. The most common grade 1-2 adverse events were fatigue (35.6%), increased liver enzymes (28.9%), hipokalemia (13.3%) and fluid retention (11.1%). Conclusions: Abiraterone was a well tolerated drug that has shown to be active in prostate cancer patients previously treated with taxans, so it has been postulated as an alternative in this pathology.
710			_9320 _aServicio de Farmacia Hospitalaria
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16688.pdf _ySolicitar documento
942			_2ddc _cART _n0